Nexentis Technologies (NXTS) and Its Rivals Financial Analysis

Nexentis Technologies (NASDAQ:NXTS – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Nexentis Technologies to similar companies based on the strength of its dividends, institutional ownership, risk, earnings, analyst recommendations, profitability and valuation.

Risk & Volatility

Nexentis Technologies has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Nexentis Technologies’ rivals have a beta of -3.72, meaning that their average stock price is 472% less volatile than the S&P 500.

Profitability

This table compares Nexentis Technologies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexentis Technologies N/A -304.79% -178.91%
Nexentis Technologies Competitors -2,372.59% -220.82% -15.99%

Institutional and Insider Ownership

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Nexentis Technologies and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nexentis Technologies $210,000.00 -$4.00 million -0.01
Nexentis Technologies Competitors $3.52 billion $3.15 billion 550.65

Nexentis Technologies’ rivals have higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nexentis Technologies and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexentis Technologies 1 0 0 0 1.00
Nexentis Technologies Competitors 7782 13876 25773 1035 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.77%. Given Nexentis Technologies’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Nexentis Technologies has less favorable growth aspects than its rivals.

Summary

Nexentis Technologies rivals beat Nexentis Technologies on 10 of the 13 factors compared.

About Nexentis Technologies

(Get Free Report)

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

Receive News & Ratings for Nexentis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexentis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.